JAGX•JAGX•Jaguar Health initiated a strategic alternatives review ahead of its anticipated New Drug Application for crofelemer to treat rare intestinal failure diseases. Crofelemer showed up to 37% parenteral support reduction in trials, in a market sized at $1.1 billion in 2026 and rising to $1.5 billion by 2033.
Jaguar Health’s board of directors has initiated a formal process to explore a range of strategic alternatives aimed at maximizing stockholder value. The review is designed to align with the anticipated completion of clinical work supporting the New Drug Application for crofelemer in rare intestinal failure diseases.
The company is targeting a timely NDA submission for its plant-derived crofelemer prescription candidate once pivotal clinical studies conclude. CEO Lisa Conte will present a program update at the Life Sciences Virtual Investor Forum on June 24, 2026 to discuss development progress and regulatory plans.
In an investigator-initiated proof-of-concept trial involving pediatric patients with microvillus inclusion disease and short bowel syndrome, crofelemer achieved up to a 37% reduction in parenteral nutritional support. A late-breaking abstract detailing these results is slated for presentation at the ESPGHAN Annual Meeting in June 2026.
Third-party analysis projects the global nutritional support market for microvillus inclusion disease at $1.1 billion in 2026, climbing to $1.5 billion by 2033. Potential strategic transactions under consideration include mergers, acquisitions, partnerships, joint ventures and licensing arrangements across both biotech and non-biotech sectors.
